TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen

Inclusion Criteria * Clinical diagnosis of pulmonary \&/or extrapulmonary TB confirmed by a positive culture and susceptibility to rifampin. Patients having isoniazid or pyrazinamide (PZA)-resistant isolates are eligible to continue in the study on a modified regimen * Evidence of HIV infection confirmed by a positive serologic test (ELISA and Western Blot). * Absolute neutrophil count \>500/mm3 (use of colony stimulating factors, filgrastim, or sargramostim is allowed) * \> 18 years of age * Willingness to practice effective contraception if applicable * Signed informed consent Exclusion Criteria * Pregnancy or breastfeeding * AST \> 10 times the upper limit of normal * Bilirubin \> 3.0 times the upper limit of normal * Creatinine \> 3.0 times the upper limit of normal * Intolerance to any of the study drugs except isoniazid or pyrazinamide * Concomitant disorder that is contraindication to the use of the study drugs * More than 28 days of treatment for active tuberculosis within the 6 months prior to this course of therapy * Bone/joint tuberculosis or silicotuberculosis